Agoracom: Small Cap Investment - Zenith Epigenetics

...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Reply New Message

Back To Forum List View

Jan 09, 2016 08:40AM

Jan 09, 2016 08:53AM

Stock2740

Rank: Treasurer [?]

Points: 330 [?]

Votes: 10 Score: 2.2 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Re: prostate drug

posted on Jan 09, 2016 08:59PM

I believe if enzalutamide and abiraterone are current best treatment for cancer ( prostrate) then ZEN-3694 hopefully will be best trail design to magnify patient quality of life and demonstrate synergistic abilities , Stock

2 Recommendations

Reply New Message

Back To Forum List View

Please to post a reply